Analyst Price Target is $3.90
▲ +864.39% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Spruce Biosciences in the last 3 months. The average price target is $3.90, with a high forecast of $10.00 and a low forecast of $1.50. The average price target represents a 864.39% upside from the last price of $0.40.
Current Consensus is
Hold
The current consensus among 9 polled investment analysts is to hold stock in Spruce Biosciences. This rating has held steady since February 2024, when it changed from a Buy consensus rating.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Read More
